1. Efficacy and safety of immune checkpoint inhibitors for hepatocellular carcinoma patients with macrovascular invasion or extrahepatic spread: a systematic review and meta-analysis of 54 studies with 6187 hepatocellular carcinoma patients

   • Cheng-Long Han
   • Bao-Wen Tian
   • Tao Li

   Review 22 February 2023 Pages: 1957 - 1969

   

2. Tumour microenvironment as a predictive factor for immunotherapy in non-muscle-invasive bladder cancer

   • Aleksandra Semeniuk-Wojtaś
   • Karolina Poddębniak-Strama
   • Rafał Stec

   Review Open access 16 March 2023 Pages: 1971 - 1989

   

3. Multidisciplinary recommendations for essential baseline functional and laboratory tests to facilitate early diagnosis and management of immune-related adverse events among cancer patients

   • Berna C. Özdemir
   • Cristina Espinosa da Silva
   • Sacha I. Rothschild

   Review Open access 05 April 2023 Pages: 1991 - 2001

4. Correction to: Multidisciplinary recommendations for essential baseline functional and laboratory tests to facilitate early diagnosis and management of immune‑related adverse events among cancer patients

   • Berna C. Özdemir
   • Cristina Espinosa da Silva
   • Sacha I. Rothschild

   Correction Open access 08 May 2023 Pages: 2003 - 2004

5. Association of medical comorbidities and cardiovascular disease with toxicity and survival among patients receiving checkpoint inhibitor immunotherapy

   • Andrew C. Johns
   • Mike Yang
   • Carolyn J. Presley

   Research 04 February 2023 Pages: 2005 - 2013

   

6. The role of spatial interplay patterns between PD-L1-positive tumor cell and T cell in recurrence of locally advanced non-small cell lung cancer

   • Liying Yang
   • Wei Zhang
   • Xiaorong Sun

   Research 04 February 2023 Pages: 2015 - 2027

   

7. Overcoming cancer-associated fibroblast-induced immunosuppression by anti-interleukin-6 receptor antibody

   • Noriyuki Nishiwaki
   • Kazuhiro Noma
   • Toshiyoshi Fujiwara

   Research Open access 10 February 2023 Pages: 2029 - 2044

   

8. Preliminary clinical study of personalized neoantigen vaccine therapy for microsatellite stability (MSS)-advanced colorectal cancer

   • Yao-Jun Yu
   • Na Shan
   • Zhen-Zhai Cai

   Research Open access 16 February 2023 Pages: 2045 - 2056

   

9. Cisplatin resistance driver claspin is a target for immunotherapy in urothelial carcinoma

   • Shuhei Yamada
   • Haruka Miyata
   • Toshihiko Torigoe

   Research 16 February 2023 Pages: 2057 - 2065

   

10. Mean platelet volume, thrombocytosis, and survival in non-small cell lung cancer patients treated with first-line pembrolizumab alone or with chemotherapy

    • Mingjia Li
    • Songzhu Zhao
    • Dwight H. Owen

    Research 16 February 2023 Pages: 2067 - 2074

    

11. The 27-gene IO score is associated with efficacy of PD-1/L1 inhibitors independent of FGFR expression in a real-world metastatic urothelial carcinoma cohort

    • Tyler J. Nielsen
    • Matthew G. Varga
    • Kimberly McGregor

    Research Open access 19 February 2023 Pages: 2075 - 2086

    

12. Expression of soluble CD27 in extranodal natural killer/T-cell lymphoma, nasal type: potential as a biomarker for diagnosis and CD27/CD70-targeted therapy

    • Toshihiro Nagato
    • Hiroki Komatsuda
    • Hiroya Kobayashi

    Research 22 February 2023 Pages: 2087 - 2098

    

13. Associations between KIR/KIR-ligand genotypes and clinical outcome for patients with advanced solid tumors receiving BEMPEG plus nivolumab combination therapy in the PIVOT-02 trial

    • A. S. Feils
    • A. K. Erbe
    • P. M. Sondel

    Research Open access 23 February 2023 Pages: 2099 - 2111

    

14. Alanine-based spacers promote an efficient antigen processing and presentation in neoantigen polypeptide vaccines

    • Carmen Aguilar-Gurrieri
    • Ana Barajas
    • Jorge Carrillo

    Research Open access 23 February 2023 Pages: 2113 - 2125

    

15. The role of blood cholesterol quality in patients with advanced cancer receiving immune checkpoint inhibitors

    • Fabiana Perrone
    • Elda Favari
    • Sebastiano Buti

    Research 24 February 2023 Pages: 2127 - 2135

    

16. Effectiveness and tolerability of camrelizumab combined with molecular targeted therapy for patients with unresectable or advanced HCC

    • Ting Li
    • Jiang Guo
    • Fanpu Ji

    Research Open access 25 February 2023 Pages: 2137 - 2149

    

17. Mitochondrial C1QBP is essential for T cell antitumor function by maintaining mitochondrial plasticity and metabolic fitness

    • Hui Tian
    • Dafei Chai
    • Junnian Zheng

    Research 25 February 2023 Pages: 2151 - 2168

    

18. Risk factors indicating immune-related adverse events with combination chemotherapy with immune checkpoint inhibitors and platinum agents in patients with non-small cell lung cancer: a multicenter retrospective study

    • Airi Fujimoto
    • Yoshimichi Koutake
    • Yosei Kawamata

    Research 27 February 2023 Pages: 2169 - 2178

    

19. LILRB2-containing small extracellular vesicles from glioblastoma promote tumor progression by promoting the formation and expansion of myeloid-derived suppressor cells

    • Peitao Wu
    • Yuhang Guo
    • Zhiyuan Qian

    Research Open access 28 February 2023 Pages: 2179 - 2193

    

20. Correction to: LILRB2-containing small extracellular vesicles from glioblastoma promote tumor progression by promoting the formation and expansion of myeloid-derived suppressor cells

    • Peitao Wu
    • Yuhang Guo
    • Zhiyuan Qian

    Correction Open access 17 April 2023 Pages: 2195 - 2196

    

21. Effectiveness and safety of radiotherapy plus programmed death-1 inhibitors and lenvatinib in patients with advanced biliary tract carcinoma: a real-world study

    • Yunchao Wang
    • Xiaobo Yang
    • Haitao Zhao

    Research 01 March 2023 Pages: 2197 - 2204

    

22. Clinicopathological significance of peritumoral alveolar macrophages in patients with resected early-stage lung squamous cell carcinoma

    • Yu Tanaka
    • Tokiko Nakai
    • Genichiro Ishii

    Research 02 March 2023 Pages: 2205 - 2215

    

23. Immune-related toxicity and soluble profile in patients affected by solid tumors: a network approach

    • Andrea Botticelli
    • Alessio Cirillo
    • Paolo Marchetti

    Research Open access 03 March 2023 Pages: 2217 - 2231

    

24. M2 tumor-associated macrophages resist to oxidative stress through heme oxygenase-1 in the colorectal cancer tumor microenvironment

    • Misato Ito
    • Kosaku Mimura
    • Koji Kono

    Research 04 March 2023 Pages: 2233 - 2244

    

25. MIP3α as an early prognostic predictor for patients with B-cell malignancies receiving CD19/CD22-redirected CAR-T cell cocktail therapy

    • Jin Jin
    • Tianjiao Liu
    • Jianfeng Zhou

    Research Open access 04 March 2023 Pages: 2245 - 2256

    

26. Neoadjuvant Camrelizumab for Non-Small Cell Lung Cancer: A Retrospective Multicenter, Real-World Study (CTONG2004)

    • Si-Yang Liu
    • Qixun Chen
    • Yi-Long Wu

    Research 05 March 2023 Pages: 2257 - 2265

    

27. A randomised controlled trial of long NY-ESO-1 peptide-pulsed autologous dendritic cells with or without alpha-galactosylceramide in high-risk melanoma

    • Nathaniel Dasyam
    • Katrina J. Sharples
    • Ian F. Hermans

    Research Open access 07 March 2023 Pages: 2267 - 2282

    

28. Targeting CD73 increases therapeutic response to immunogenic chemotherapy by promoting dendritic cell maturation

    • Yun-Shan Lin
    • Shu-Fen Chiang
    • Kevin Chih-Yang Huang

    Research 07 March 2023 Pages: 2283 - 2297

    

29. Efficacy and safety of immune checkpoint inhibitors in elderly patients with primary liver cancer: a retrospective, multicenter, real-world cohort study

    • Lushan Xiao
    • Yanxia Liao
    • Li Liu

    Research 08 March 2023 Pages: 2299 - 2308

    

30. HER2-targeting antibody–drug conjugate RC48 alone or in combination with immunotherapy for locally advanced or metastatic urothelial carcinoma: a multicenter, real-world study

    • Meiting Chen
    • Kai Yao
    • Xin An

    Research Open access 10 March 2023 Pages: 2309 - 2318

    

31. CiTSA: a comprehensive platform provides experimentally supported signatures of cancer immunotherapy and analysis tools based on bulk and scRNA-seq data

    • Feng Li
    • Kejing Dong
    • Xia Li

    Research 13 March 2023 Pages: 2319 - 2330

    

32. Preclinical development and evaluation of nanobody-based CD70-specific CAR T cells for the treatment of acute myeloid leukemia

    • Jiali Cheng
    • Tong Ge
    • Liang Huang

    Research Open access 17 March 2023 Pages: 2331 - 2346

    

33. Establishment of a novel NFAT-GFP reporter platform useful for the functional avidity maturation of HLA class II-restricted TCRs

    • Fumihiro Fujiki
    • Soyoko Morimoto
    • Haruo Sugiyama

    Research Open access 20 March 2023 Pages: 2347 - 2356

    

34. A phase I prospective, non-randomized trial of autologous dendritic cell-based cryoimmunotherapy in patients with metastatic castration-resistant prostate cancer

    • Liv Cecilie Vestrheim Thomsen
    • Alfred Honoré
    • Christian Beisland

    Research Open access 20 March 2023 Pages: 2357 - 2373

    

35. Identification of antigenic epitopes recognized by tumor infiltrating lymphocytes in high grade serous ovarian cancer by multi-omics profiling of the auto-antigen repertoire

    • Douglas G. Millar
    • S. Y. Cindy Yang
    • Pamela S. Ohashi

    Research Open access 21 March 2023 Pages: 2375 - 2392

    

36. IL13Rα2-targeted third-generation CAR-T cells with CD28 transmembrane domain mediate the best anti-glioblastoma efficacy

    • Aiqin Gu
    • Yue Bai
    • Xiaosong Zhong

    Research 29 March 2023 Pages: 2393 - 2403

    

37. Immune checkpoint inhibition combined with targeted therapy using a novel virus-like drug conjugate induces complete responses in a murine model of local and distant tumors

    • Ruben V. Huis in ‘t Veld
    • Sen Ma
    • Martine J. Jager

    Research Open access 30 March 2023 Pages: 2405 - 2422

    

38. Integrative analyses of bulk and single-cell RNA-seq identified cancer-associated fibroblasts-related signature as a prognostic factor for immunotherapy in NSCLC

    • Shasha Wang
    • Guangyu Fan
    • Xiaohong Han

    Research 03 April 2023 Pages: 2423 - 2442

    

39. First-in-human study of oleclumab, a potent, selective anti-CD73 monoclonal antibody, alone or in combination with durvalumab in patients with advanced solid tumors

    • Johanna Bendell
    • Patricia LoRusso
    • Sandip Pravin Patel

    Research Open access 05 April 2023 Pages: 2443 - 2458

    

40. Factors impacting the efficacy of the in-situ vaccine with CpG and OX40 agonist

    • Alexander A. Pieper
    • Dan V. Spiegelman
    • Paul M. Sondel

    Research Open access 05 April 2023 Pages: 2459 - 2471

    

41. Combined therapeutic effect of YHO-1701 with PD-1 blockade is dependent on natural killer cell activity in syngeneic mouse models

    • Hiroyuki Takahashi
    • Nao Miyoshi
    • Akira Asai

    Research 05 April 2023 Pages: 2473 - 2482

    

42. The landscape of objective response rate of anti-PD-1/L1 monotherapy across 31 types of cancer: a system review and novel biomarker investigating

    • Yize Mao
    • Hui Xie
    • Wei Wang

    Research 06 April 2023 Pages: 2483 - 2498

    

43. CD33 BiTE^® molecule-mediated immune synapse formation and subsequent T-cell activation is determined by the expression profile of activating and inhibitory checkpoint molecules on AML cells

    • Anetta Marcinek
    • Bettina Brauchle
    • Marion Subklewe

    Research Open access 11 April 2023 Pages: 2499 - 2512

    

44. Correction to: CD33 BiTE^® molecule-mediated immune synapse formation and subsequent T-cell activation is determined by the expression profile of activating and inhibitory checkpoint molecules on AML cells

    • Anetta Marcinek
    • Bettina Brauchle
    • Marion Subklewe

    Correction Open access 08 May 2023 Pages: 2513 - 2514

    

45. Pembrolizumab near the end of life in patients with metastatic pancreatic cancer: a multi-site consecutive series to examine survival and patient treatment burden

    • Michael H. Storandt
    • Nguyen Tran
    • Aminah Jatoi

    Brief Report 06 March 2023 Pages: 2515 - 2520

    

46. Anti-PD-1 therapy in advanced sarcomas: is cutaneous primary site a stronger predictor of response than histologic subtype?

    • Ruoyu Miao
    • Jennifer Swank
    • Andrew S. Brohl

    Brief Report Open access 13 March 2023 Pages: 2521 - 2527

    

47. BTLA dysregulation correlates with poor outcome and diminished T cell-mediated antitumor responses in chronic lymphocytic leukemia

    • Christian Sordo-Bahamonde
    • Seila Lorenzo-Herrero
    • Segundo Gonzalez

    Brief Report Open access 11 April 2023 Pages: 2529 - 2539

    

48. Cancer immunity and immunotherapy beyond COVID-19

    • Matteo Bellone
    • Arianna Brevi
    • Mario Paolo Colombo

    Meeting Report 30 March 2023 Pages: 2541 - 2548